全文获取类型
收费全文 | 6218篇 |
免费 | 570篇 |
国内免费 | 47篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 118篇 |
妇产科学 | 298篇 |
基础医学 | 735篇 |
口腔科学 | 142篇 |
临床医学 | 697篇 |
内科学 | 1368篇 |
皮肤病学 | 79篇 |
神经病学 | 611篇 |
特种医学 | 359篇 |
外科学 | 696篇 |
综合类 | 144篇 |
一般理论 | 2篇 |
预防医学 | 370篇 |
眼科学 | 168篇 |
药学 | 357篇 |
中国医学 | 63篇 |
肿瘤学 | 581篇 |
出版年
2023年 | 31篇 |
2022年 | 56篇 |
2021年 | 141篇 |
2020年 | 88篇 |
2019年 | 182篇 |
2018年 | 207篇 |
2017年 | 168篇 |
2016年 | 190篇 |
2015年 | 239篇 |
2014年 | 271篇 |
2013年 | 334篇 |
2012年 | 437篇 |
2011年 | 468篇 |
2010年 | 303篇 |
2009年 | 282篇 |
2008年 | 332篇 |
2007年 | 302篇 |
2006年 | 357篇 |
2005年 | 264篇 |
2004年 | 269篇 |
2003年 | 239篇 |
2002年 | 204篇 |
2001年 | 160篇 |
2000年 | 144篇 |
1999年 | 123篇 |
1998年 | 62篇 |
1997年 | 56篇 |
1996年 | 50篇 |
1995年 | 30篇 |
1994年 | 36篇 |
1993年 | 33篇 |
1992年 | 76篇 |
1991年 | 74篇 |
1990年 | 58篇 |
1989年 | 65篇 |
1988年 | 39篇 |
1987年 | 42篇 |
1986年 | 50篇 |
1985年 | 38篇 |
1984年 | 33篇 |
1983年 | 33篇 |
1982年 | 25篇 |
1981年 | 23篇 |
1979年 | 21篇 |
1978年 | 19篇 |
1977年 | 16篇 |
1975年 | 14篇 |
1974年 | 30篇 |
1973年 | 21篇 |
1972年 | 18篇 |
排序方式: 共有6835条查询结果,搜索用时 15 毫秒
1.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
2.
3.
4.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
5.
Nonsurgical management of partial adhesive small-bowel obstruction with oral therapy: a randomized controlled trial 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Canadian Medical Association journal》网站下载免费的PDF全文](/ch/ext_images/free.gif)
6.
7.
Feng-Yuan Liu Chien-Yu Lin Joseph T Chang Shu-Hang Ng Shy-Chyi Chin Hung-Ming Wang Chun-Ta Liao Sheng-Chieh Chan Tzu-Chen Yen 《Journal of nuclear medicine》2007,48(10):1614-1619
Conventional work-up (CWU) with chest radiography, abdominal ultrasonography, and skeletal scintigraphy has limited value in M staging of nonkeratinizing nasopharyngeal carcinoma (NPC). Our aim was to evaluate whether (18)F-FDG PET could replace CWU by comparing their diagnostic efficacies. METHODS: Patients with histologically proven nonkeratinizing NPC and no prior treatment were prospectively enrolled. All study participants underwent CWU and (18)F-FDG PET for primary M staging. Distant metastasis was considered to be present if there was any reliable evidence identified within 1 y after diagnosis. The comparative diagnostic efficacies of (18)F-FDG PET, CWU, and the combination of (18)F-FDG PET and CWU (PET+CWU) were evaluated using the areas under the receiver-operating-characteristic (ROC) curves. RESULTS: Sixty-one (20.3%) of 300 eligible patients were found to have distant metastases. On a patient-based analysis, (18)F-FDG PET was found to be more effective than CWU (P < 0.001), whereas it was equally effective with PET+CWU (P = 0.130). On region-based analyses, (18)F-FDG PET was more effective than skeletal scintigraphy and chest radiography for detecting bone metastases (P < 0.001) and chest metastases (P < 0.001), respectively. (18)F-FDG PET and abdominal ultrasound were equally effective for detecting hepatic metastases (P = 0.127). On region-based analyses, the combination of (18)F-FDG PET and CWU did not yield any noticeable increase in diagnostic efficacy. CONCLUSION: (18)F-FDG PET can replace CWU in primary M staging of nonkeratinizing NPC. 相似文献
8.
9.
10.